These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 11489795)

  • 41. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
    Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
    Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer.
    Harima Y; Harima K; Sawada S; Tanaka Y; Arita S; Ohnishi T
    Clin Cancer Res; 2000 Mar; 6(3):1079-85. PubMed ID: 10741737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
    Schlichtholz B; Presler M; Matuszewski M
    Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
    Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
    Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
    Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
    Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TP53 gene in blood plasma DNA of tumor patients.
    Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
    Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prognostic value of p53 immunostaining in node-negative breast carcinoma.
    Soontrapornchai P; Chanvitan A; Koontongkaew S; Sunpaweravong S
    J Med Assoc Thai; 2007 Sep; 90(9):1833-8. PubMed ID: 17957927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers.
    Silvestrini R; Daidone MG; Benini E; Faranda A; Tomasic G; Boracchi P; Salvadori B; Veronesi U
    Clin Cancer Res; 1996 Dec; 2(12):2007-13. PubMed ID: 9816160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy.
    Dinshaw KA; Budrukkar AN; Chinoy RF; Sarin R; Badwe R; Hawaldar R; Shrivastava SK
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1132-41. PubMed ID: 15978744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression.
    Parikh RR; Yang Q; Higgins SA; Haffty BG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):35-42. PubMed ID: 17855007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients.
    Austrup F; Uciechowski P; Eder C; Böckmann B; Suchy B; Driesel G; Jäckel S; Kusiak I; Grill HJ; Giesing M
    Br J Cancer; 2000 Dec; 83(12):1664-73. PubMed ID: 11104564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.